Evidence map›Paper›PMID 36608483›Full record

ArticleDrug and alcohol dependence2023

Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder.

Victor M Karpyak, Brandon J Coombes, Jennifer R Geske, Vanessa M Pazdernik, Terry Schneekloth, Bhanu Prakash Kolla, Tyler Oesterle, Larissa L Loukianova, Michelle K Skime, Ada Man-Choi Ho and 5 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Victor M KarpyakDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA. Electronic address: karpyak.victor@mayo.edu.
Brandon J CoombesDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Jennifer R GeskeDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Vanessa M PazdernikDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Terry SchneeklothDepartment of Psychiatry & Psychology, Mayo Clinic, Scottdale, AZ, USA.
Bhanu Prakash KollaDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Tyler OesterleDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Larissa L LoukianovaDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Michelle K SkimeDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Ada Man-Choi HoDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
Quyen NgoHazelden Betty Ford Foundation, Center City, MN, USA.
Cedric SkillonHazelden Betty Ford Foundation, Center City, MN, USA.
Ming-Fen HoDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Richard WeinshilboumDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Joanna M BiernackaDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · USMayo Clinic in Florida · USFord Foundation · USMayo Clinic in Arizona · US

Funding

INHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9M
Alcohol Use Disorder: Acamprosate Pharmacometabolomics-informed PharmacogenomicsR01AA027486 · NIAAA · MAYO CLINIC ROCHESTER · PI Ming-Fen Ho, Richard M. Weinshilboum · 2018 to 2026
$4.0M
Pharmacogenomics of Acamprosate Treatment Outcome (Supplement)U01AA027487 · NIAAA · MAYO CLINIC ROCHESTER · PI BIERNACKA, JOANNA M, KARPYAK, VICTOR M. · 2018 to 2023
$3.7M
The Mayo Clinic Center for Individualized Treatment of Alcohol DependenceP20AA017830 · NIAAA · MAYO CLINIC ROCHESTER · PI CHOI, DOO-SUP · 2009 to 2010
$2.5M
Single cell multi-omics of iPSC-derived brain organoids from patients with opioid use disorder: synthetic opioids as molecular probesR01DA057928 · NIDA · MAYO CLINIC ROCHESTER · PI Ming-Fen Ho · 2023 to 2026
$1.7M
Acamprosate pharmacogenomics: iPSC based model of alcohol use disorderK01AA028050 · NIAAA · MAYO CLINIC ROCHESTER · PI HO, MING-FEN · 2019 to 2024
$649k
Pharmacogenomics of Treatment Outcomes in Alcohol Use DisordersR21AA025214 · NIAAA · MAYO CLINIC ROCHESTER · PI BIERNACKA, JOANNA M, KARPYAK, VICTOR M. · 2016 to 2017
$417k
IMPACT OF SEX-RELATED HORMONE LEVELS AND GENETIC VARIATION ON ALCOHOL USE DISORDERS AND RELATED PHENOTYPES IN MALES AND FEMALESR21AA026875 · NIAAA · MAYO CLINIC ROCHESTER · PI KARPYAK, VICTOR M., WINHAM, STACEY J · 2019 to 2020
$417k
NIAAA NIH HHS K01 AA028050NIAAA NIH HHS P20 AA017830NIAAA NIH HHS R01 AA027486NIAAA NIH HHS R21 AA025214NIAAA NIH HHS R21 AA026875NIAAA NIH HHS U01 AA027487NIDA NIH HHS R01 DA057928NIGMS NIH HHS R01 GM028157
6 · The paper itself

Abstract

Lifetime history of major depressive disorder (MDD) has a sex-specific association with pretreatment alcohol consumption in patients with alcohol dependence. Here, we investigated the association of genetic load for MDD estimated using a polygenic risk score (PRS) with pretreatment alcohol consumption assessed with Timeline Follow Back in a sample of 287 men and 156 women meeting DSM-IV-TR criteria for alcohol dependence. Preferred drinking situations were assessed using the Inventory of Drug Taking Situations (IDTS). Linear models were used to test for association of normalized alcohol consumption measures with the MDD-PRS, adjusting for ancestry, age, sex, and number of days sober at baseline. We fit models both with and without adjustment for MDD history and alcohol-use-related PRSs as covariates. Higher MDD-PRS was associated with lower 90-day total alcohol consumption in men (β = -0.16, p = 0.0012) but not in women (β = 0.11, p = 0.18). The association of MDD-PRS with IDTS measures was also sex-specific: higher MDD-PRS was associated with higher propensity to drink in temptation-related situations in women, while the opposite (negative association)was found in men. MDD-PRS was not associated with lifetime MDD history in our sample, and adjustment for lifetime MDD and alcohol-related PRSs did not impact the results. Our results suggest that genetic load for MDD impacts pretreatment alcohol consumption in a sex-specific manner, which is similar to, but independent from, the effect of history of MDD. The clinical implications of these findings and contributing biological and psychological factors should be investigated in future studies.

Indexed as

AlcoholismMajor Depressive DisorderAlcohol DrinkingFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleMultifactorial InheritanceRisk FactorsAlcohol consumptionAlcohol use disorderDepressionPolygenic risk scoresSex differences

Identifiers

PMID36608483
PMCPMC9869363
OpenAlexW4312204574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.